This is a observational study aimed at evaluating miRNA 371a-3p (miRNA 371) as a specific marker for presence or absence of clinically detectable viable germ cell malignancy.
Patients must be ≥ 18 years of age.
Patients must have a new diagnosis of a germ cell tumor confirmed pathologically or serologically (diagnostic elevation of HCG/AFP). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible.
If surgery is planned, male patients with Clinical Stage I testicular cancer must have orchiectomy completed within 42 days prior to registration.
Patients must have risk of relapse assessment determined by the local investigator prior to registration.
Patients with high risk of relapse or metastatic disease.
Patients with tumour assessments beyond the time frame required by the protocol.
Patients not complaint with the protocol schedule.